Literature DB >> 2679910

Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase.

J L Niles1, R T McCluskey, M F Ahmad, M A Arnaout.   

Abstract

Circulating IgG autoantibodies that produce cytoplasmic immunofluorescence staining of ethanol-fixed normal neutrophils have recently been found in a large percentage of patients with active Wegener's granulomatosis. Such autoantibodies are rarely found in other diseases and are therefore virtually diagnostic of Wegener's granulomatosis. The nature of the neutrophil antigen defined by these autoantibodies is controversial and the roles of the antigen and/or autoantibodies in the pathogenesis of Wegener's granulomatosis are unknown. We studied serum samples that produce the cytoplasmic pattern of staining from 10 patients with a diagnosis of Wegener's granulomatosis. By Western blot analysis, all 10 sera reacted with a 29-Kd neutrophil protein (p29). We generated a mouse monoclonal antibody directed against this antigen. The monoclonal antibody produced the same immunofluorescence staining pattern as the serum autoantibodies and was used to affinity-purify p29. The purified antigen had a novel N-terminal sequence homologous to members of the serine proteinase family and bound to radiolabeled diisopropyl fluorophosphate (DFP). We conclude that the neutrophil antigen responsible for the cytoplasmic staining pattern produced by autoantibodies in patients with active Wegener's granulomatosis is a distinctive serine proteinase.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2679910

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  96 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 2.  Rare diseases.3: Wegener's granulomatosis.

Authors:  C A Langford; G S Hoffman
Journal:  Thorax       Date:  1999-07       Impact factor: 9.139

3.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 4.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

5.  The use of small molecule high-throughput screening to identify inhibitors of the proteinase 3-NB1 interaction.

Authors:  M Choi; C Eulenberg; S Rolle; J P von Kries; F C Luft; R Kettritz
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

6.  Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate.

Authors:  W Pollock; K Clarke; K Gallagher; J Hall; E Luckhurst; R McEvoy; J Melny; J Neil; A Nikoloutsopoulos; T Thompson; M Trevisin; J Savige
Journal:  J Clin Pathol       Date:  2002-09       Impact factor: 3.411

7.  Human neutrophil azurocidin synergizes with leukocyte elastase and cathepsin G in the killing of Capnocytophaga sputigena.

Authors:  K T Miyasaki; A L Bodeau
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 8.  The antigenic significance and methods of detection of the anti-neutrophil cytoplasmic autoantibodies (ANCA).

Authors:  X Bosch; R A Asherson
Journal:  Postgrad Med J       Date:  1992-09       Impact factor: 2.401

9.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 10.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.